Our strength is in our breadth
18 December 2020
AMCA Chair and recently appointed Drive Change Ambassador, Lucy Haslam, attended the inaugural Drive Change Friends & Supporters meeting. We are delighted to see our own AMCA Ambassadors, David Heilpern and Mick Palmer, working alongside Fiona Patten, MP and the rest of the committed Drive Change team, campaigning tirelessly for drug driving law reform for patients using medicinal cannabis.
AMCA and its partner organisation, SCCAC, are proud to continue to support Drive Change in its commitment to help create drug driving law reform that’s fair, equal, and improves public health.
18 December 2020
AMCA is lodging a submission to the ODC on behalf of our members regarding Medicinal Cannabis Permit reform.
17 December 2020
AMCA Company Secretary and Lawyer, Dr. Teresa Nicoletti provided our opinion for a Cannabiz article on the TGA down-scheduling decision on cannabidiol.
16 December 2020
We held the first of our Interest Groups, as outlined during our AGM, on 16th December. This Industry/Regulatory/Legal Interest Group focused on two topics - 1. GMP requirements for imported medicinal cannabis products to those that are domestically manufactured and 2. ODC Medicinal Cannabis Permit Reform. The meeting was very well attended by 25 members and input from the meeting is being used in submissions from the AMCA for consultations regarding these topics by the TGA and ODC respectively.
Our inaugural AGM was held on 28th October and was extremely well attended. Thanks to the nearly 60 of our members who joined the Zoom meeting and to Rhys Cohen for providing essential technical assistance!
The AGM introduced our members to AMCA's Founders, Board and Ambassadors as well as its Foundation Partners and Collaborative Partners (see our website for more).
Lucy Haslam, the Chair, presented AMCA's Vision, Mission and belief that it is essential to have a broad mix of members to meet the needs of each facet of the complex medicinal cannabis industry. Our current membership of more than 90 individuals and organisations, from patients and their HCPs through to industry and research, reflects this diversity.
The GM, Gail Wiseman, outlined the Association's priorities, actions to date and plans for the future, including a new structure to enable members' voices to be heard, issues raised and action plans and solutions to be produced.
During the meeting, eligible members were invited to vote for an additional Industry Board Director from 6 high calibre nominees. Joel Hardy from Cymra Life Sciences was elected. We congratulate Joel on his appointment and thank all of the nominees who put themselves forward for election.